Why is bridging therapy commonly used when starting warfarin?

Study for the Anticoagulation and ACS Exam with tailored flashcards and multiple choice questions, each featuring hints and detailed explanations. Prepare effectively and ensure success on your exam with confidence!

Multiple Choice

Why is bridging therapy commonly used when starting warfarin?

Explanation:
When you start warfarin, its effect isn’t immediate. Warfarin blocks production of vitamin K–dependent clotting factors, but the body already has circulating factors, and the full anticoagulant effect takes several days to develop. In addition, levels of protein C and protein S drop quickly, which can create a temporary prothrombotic state at the start of therapy. To protect against early clotting during this vulnerable period, a fast-acting parenteral anticoagulant given by injection or IV is used and continued until the INR is in the therapeutic range. This bridging approach provides immediate protection while warfarin’s slower onset takes effect. Using aspirin as a bridge isn’t appropriate because aspirin is an antiplatelet agent and does not provide the needed anticoagulation coverage; it also adds bleeding risk without reliably preventing thromboembolism during the initial days of warfarin therapy.

When you start warfarin, its effect isn’t immediate. Warfarin blocks production of vitamin K–dependent clotting factors, but the body already has circulating factors, and the full anticoagulant effect takes several days to develop. In addition, levels of protein C and protein S drop quickly, which can create a temporary prothrombotic state at the start of therapy. To protect against early clotting during this vulnerable period, a fast-acting parenteral anticoagulant given by injection or IV is used and continued until the INR is in the therapeutic range. This bridging approach provides immediate protection while warfarin’s slower onset takes effect. Using aspirin as a bridge isn’t appropriate because aspirin is an antiplatelet agent and does not provide the needed anticoagulation coverage; it also adds bleeding risk without reliably preventing thromboembolism during the initial days of warfarin therapy.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy